Illumina (ILMN) | Financial Analysis & Statements
Illumina, Inc. Large-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
1.2B
Gross Profit
759.0M
65.49%
Operating Income
211.0M
18.21%
Net Income
334.0M
28.82%
EPS (Diluted)
$2.16
Balance Sheet Metrics
Total Assets
6.6B
Total Liabilities
3.9B
Shareholders Equity
2.7B
Debt to Equity
1.44
Cash Flow Metrics
Operating Cash Flow
450.0M
Free Cash Flow
266.0M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Illumina Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 4.3B | 4.4B | 4.5B | 4.6B | 4.5B |
| Cost of Goods Sold | 1.5B | 1.5B | 1.8B | 1.6B | 1.4B |
| Gross Profit | 2.9B | 2.9B | 2.7B | 3.0B | 3.2B |
| Gross Margin % | 66.1% | 65.4% | 60.9% | 64.8% | 69.7% |
| Operating Expenses | |||||
| Research & Development | 967.0M | 1.2B | 1.4B | 1.3B | 1.2B |
| Selling, General & Administrative | 1.1B | 1.1B | 1.6B | 1.3B | 2.1B |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 2.1B | 2.3B | 3.0B | 2.6B | 3.3B |
| Operating Income | 817.0M | 600.0M | -222.0M | 354.0M | -123.0M |
| Operating Margin % | 18.8% | 13.7% | -4.9% | 7.7% | -2.7% |
| Non-Operating Items | |||||
| Interest Income | 40.0M | 46.0M | 58.0M | 11.0M | 0 |
| Interest Expense | 101.0M | 100.0M | 77.0M | 26.0M | 61.0M |
| Other Non-Operating Income | 330.0M | -1.7B | -876.0M | -4.7B | 1.1B |
| Pre-tax Income | 1.1B | -1.2B | -1.1B | -4.3B | 884.0M |
| Income Tax | 236.0M | 44.0M | 44.0M | 68.0M | 122.0M |
| Effective Tax Rate % | 21.7% | 0.0% | 0.0% | 0.0% | 13.8% |
| Net Income | 850.0M | -1.2B | -1.2B | -4.4B | 762.0M |
| Net Margin % | 19.6% | -28.0% | -25.8% | -96.1% | 16.8% |
| Key Metrics | |||||
| EBITDA | 1.5B | 708.0M | 269.0M | 746.0M | 137.0M |
| EPS (Basic) | $5.47 | $-7.69 | $-7.34 | $-28.00 | $5.07 |
| EPS (Diluted) | $5.45 | $-7.69 | $-7.34 | $-28.00 | $5.04 |
| Basic Shares Outstanding | 155000000 | 159000000 | 158000000 | 157000000 | 150000000 |
| Diluted Shares Outstanding | 155000000 | 159000000 | 158000000 | 157000000 | 150000000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Illumina Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 1.4B | 1.1B | 1.0B | 2.0B | 1.2B |
| Short-term Investments | 215.0M | 93.0M | 6.0M | 26.0M | 107.0M |
| Accounts Receivable | 854.0M | 735.0M | 734.0M | 671.0M | 648.0M |
| Inventory | 564.0M | 547.0M | 587.0M | 568.0M | 431.0M |
| Other Current Assets | 238.0M | 244.0M | 234.0M | 285.0M | 295.0M |
| Total Current Assets | 3.3B | 2.7B | 2.6B | 3.6B | 2.7B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 370.0M | 419.0M | 544.0M | 653.0M | 672.0M |
| Goodwill | 2.4B | 2.5B | 8.1B | 9.8B | 17.5B |
| Intangible Assets | 210.0M | 295.0M | 3.0B | 3.3B | 3.2B |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 903.0M | 915.0M | 413.0M | 423.0M | 445.0M |
| Total Non-Current Assets | 3.4B | 3.6B | 7.5B | 8.7B | 12.5B |
| Total Assets | 6.6B | 6.3B | 10.1B | 12.3B | 15.2B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 240.0M | 221.0M | 245.0M | 293.0M | 332.0M |
| Short-term Debt | 577.0M | 578.0M | 86.0M | 1.3B | 71.0M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 1.6B | 1.5B | 1.6B | 2.8B | 1.1B |
| Non-Current Liabilities | |||||
| Long-term Debt | 2.0B | 2.0B | 2.2B | 2.2B | 2.5B |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 360.0M | 339.0M | 620.0M | 649.0M | 915.0M |
| Total Non-Current Liabilities | 2.3B | 2.4B | 2.8B | 2.9B | 3.4B |
| Total Liabilities | 3.9B | 3.9B | 4.4B | 5.7B | 4.5B |
| Equity | |||||
| Common Stock | 2.0M | 2.0M | 2.0M | 2.0M | 2.0M |
| Retained Earnings | -392.0M | -1.2B | -19.0M | 1.1B | 5.5B |
| Treasury Stock | 4.7B | 3.9B | 3.8B | 3.8B | 3.7B |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 2.7B | 2.4B | 5.7B | 6.6B | 10.7B |
| Key Metrics | |||||
| Total Debt | 2.6B | 2.6B | 2.3B | 3.6B | 2.5B |
| Working Capital | 1.7B | 1.2B | 1.0B | 788.0M | 1.6B |
Balance Sheet Composition
Illumina Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 850.0M | -1.2B | -1.2B | -4.4B | 762.0M |
| Depreciation & Amortization | 270.0M | 354.0M | 432.0M | 394.0M | 251.0M |
| Stock-Based Compensation | 275.0M | 370.0M | 380.0M | 366.0M | 754.0M |
| Working Capital Changes | -145.0M | -29.0M | -116.0M | -193.0M | -189.0M |
| Operating Cash Flow | 1.4B | -956.0M | -537.0M | -4.1B | 1.4B |
| Investing Activities | |||||
| Capital Expenditures | -148.0M | -128.0M | -195.0M | -286.0M | -208.0M |
| Acquisitions | -10.0M | 2.0M | -29.0M | -85.0M | -2.4B |
| Investment Purchases | - | -52.0M | -6.0M | -40.0M | -77.0M |
| Investment Sales | - | - | 0 | 0 | 1.7B |
| Investing Cash Flow | -158.0M | -178.0M | -230.0M | -411.0M | -1.1B |
| Financing Activities | |||||
| Share Repurchases | -742.0M | -116.0M | - | 0 | 0 |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 495.0M | 1.2B | 0 | 991.0M | 988.0M |
| Debt Repayment | -500.0M | -750.0M | -1.2B | 0 | -517.0M |
| Financing Cash Flow | -744.0M | -570.0M | -1.2B | 1.0B | -51.0M |
| Free Cash Flow | 931.0M | 709.0M | 282.0M | -74.0M | 337.0M |
| Net Change in Cash | 486.0M | -1.7B | -2.0B | -3.5B | 325.0M |
Cash Flow Trend
Illumina Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
24.22
Forward P/E
22.66
Price to Book
7.42
Price to Sales
4.65
PEG Ratio
0.28
Profitability Ratios
Profit Margin
19.57%
Operating Margin
19.67%
Return on Equity
33.36%
Return on Assets
8.39%
Financial Health
Current Ratio
2.08
Debt to Equity
93.76
Beta
1.49
Per Share Data
EPS (TTM)
$5.45
Book Value per Share
$17.80
Revenue per Share
$28.02
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ILMN | 19.2B | 24.22 | 7.42 | 33.36% | 19.57% | 93.76 |
| Thermo Fisher | 174.6B | 25.84 | 3.31 | 13.52% | 15.15% | 82.91 |
| Danaher | 126.4B | 34.61 | 2.40 | 7.08% | 14.89% | 37.17 |
| Idexx Laboratories | 44.7B | 42.92 | 27.85 | 66.20% | 24.62% | 60.83 |
| Agilent Technologies | 32.7B | 25.67 | 4.76 | 19.95% | 18.26% | 51.39 |
| Waters | 30.5B | 28.90 | 7.24 | 29.28% | 20.30% | 60.28 |
Financial data is updated regularly. All figures are in the company's reporting currency.






